Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy
https://pubmed.ncbi.nlm.nih.gov/33176598/
https://journals.sagepub.com/doi/10.1177/0300891620974755?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&
Presence of SARS-CoV-2 receptor-binding domain (RBD)-specific antibodies
Blood samples of 959 asymptomatic individuals enrolled in a prospective lung cancer screening trial
Italy’s first two cases of COVID-19 disease
January 30, 2020, two tourists from China in Rome
First laboratory-confirmed Italian COVID-19 case, Lombardy on February 20, 2020,
September 2019 to March 2020
SARS-CoV-2 RBD-specific antibodies were detected in 111 of 959 (11.6%) individuals
IgM and some IgG
September 2019, 23/111
October, 27/111
November, 26/111
December, 11/111
January, 3/111
February, 21/111
Unexpected very early circulation of SARS-CoV-2 among asymptomatic individuals in Italy
At least one SARS-CoV-2–positive patient was detected in 13 regions
IgM antibodies were detected in 97 (10.1%) patients
IgG antibodies were found in 16 (1.7%)
All the patients were asymptomatic at the time of
blood sample collection.
First IgM detected 3rd September
Infection more widespread than believed
Therefore an overestimation of the mortality rate
Since November to December 2019
Many general practitioners began reporting severe respiratory symptoms in elderly
and frail people
Atypical bilateral bronchitis
(? organising pneumonia)
Attributed to aggressive forms of seasonal influenza.
National Library of Medicine
https://pubmed.ncbi.nlm.nih.gov/32371096/
Paris, December 2019
Patient hospitalized for hemoptysis
Stored nasopharyngeal swab confirmed the diagnosis of
SARS-CoV-2 infection.
Harvard Library, Since autumn 2019
https://dash.harvard.edu/handle/1/42669767
Increase of hospital traffic in the Wuhan region
Satellite imagery
COVID-19 symptoms–related queries in search engines
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
https://www.nejm.org/doi/full/10.1056/NEJMc2103916?emp=marcom&utm_source=nejmlist&utm_medium=email&utm_campaign=aomev2&utm_content=version-c
Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Efficacy 94% in phase 3 trials
Durability of protection, 180 days after 2nd dose
Antibody activity remained high in all age groups at day 209
Results are consistent with convalescent patients with Covid-19 through 8 months after symptom onset
Support the use of this vaccine in addressing the Covid-19 pandemic.
Source